{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T21:52:16Z","timestamp":1769118736360,"version":"3.49.0"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,2,27]],"date-time":"2023-02-27T00:00:00Z","timestamp":1677456000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,27]],"date-time":"2023-02-27T00:00:00Z","timestamp":1677456000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009043","name":"University of Patras","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100009043","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Digital ulcers (DUs) comprise the main manifestation of vasculopathy and are a major cause of disability in patients with systemic sclerosis (SSc). A literature search in Web of Science, PubMed and Directory of Open Access Journals was performed in December 2022 to identify articles published in the last decade regarding the management of DUs. Prostacyclin analogues, endothelin antagonists and phosphodiesterase 5 inhibitors have shown promising results both as a stand-alone treatment and in combination for the treatment of existing and prevention of new DUs. Moreover, autologous fat grafting and botulinum toxin injections, although not readily available, can be of use in recalcitrant cases. Many investigational treatments with promising results could pave the way for a paradigm shift in the treatment of DUs in the future. Despite these recent advances, challenges remain. Better-designed trials are of paramount importance to optimise DU treatment in the years to come.<jats:table-wrap><jats:table><jats:tbody>\n                    <jats:tr>\n                      <jats:td colspan=\"2\"><jats:bold>Key Points<\/jats:bold>\u2022 <jats:italic>DUs are a major cause of pain and reduced quality of life in patients with SSc.<\/jats:italic>\u2022 <jats:italic>Prostacyclin analogues and endothelin antagonists have shown promising results both as a stand-alone treatment and in combination for the treatment of existing and prevention of new DUs.<\/jats:italic>\u2022 <jats:italic>In the future, a combination of more powerful vasodilatory drugs, perhaps in conjunction with topical approaches, may improve outcomes.<\/jats:italic><\/jats:td>\n                    <\/jats:tr>\n                  <\/jats:tbody><\/jats:table><\/jats:table-wrap><\/jats:p>","DOI":"10.1007\/s10067-023-06511-0","type":"journal-article","created":{"date-parts":[[2023,2,27]],"date-time":"2023-02-27T13:03:03Z","timestamp":1677502983000},"page":"2589-2599","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Treatment of digital ulcers in systemic sclerosis: recent developments and future perspectives"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3738-3813","authenticated-orcid":false,"given":"Ioannis","family":"Sagonas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8027-3655","authenticated-orcid":false,"given":"Dimitrios","family":"Daoussis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,2,27]]},"reference":[{"key":"6511_CR1","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1038\/s41584-020-0386-4","volume":"16","author":"M Hughes","year":"2020","unstructured":"Hughes M, Allanore Y, Chung L et al (2020) Raynaud phenomenon and digital ulcers in systemic sclerosis. Nat Rev Rheumatol 16:208\u2013221. https:\/\/doi.org\/10.1038\/s41584-020-0386-4","journal-title":"Nat Rev Rheumatol"},{"key":"6511_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13075-019-2080-y","volume":"21","author":"K Morrisroe","year":"2019","unstructured":"Morrisroe K, Stevens W, Sahhar J et al (2019) Digital ulcers in systemic sclerosis: their epidemiology, clinical characteristics, and associated clinical and economic burden. Arthritis Res Ther 21:1\u201312. https:\/\/doi.org\/10.1186\/s13075-019-2080-y","journal-title":"Arthritis Res Ther"},{"key":"6511_CR3","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1093\/rheumatology\/kew047","volume":"56","author":"M Hughes","year":"2017","unstructured":"Hughes M, Herrick AL (2017) Digital ulcers in systemic sclerosis. Rheumatology 56:14\u201325. https:\/\/doi.org\/10.1093\/rheumatology\/kew047","journal-title":"Rheumatology"},{"key":"6511_CR4","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s40674-018-0102-6","volume":"4","author":"AM Hinze","year":"2018","unstructured":"Hinze AM, Wigley FM (2018) Pharmacotherapy options in the management of Raynaud\u2019s phenomenon. Curr Treatm Opt Rheumatol 4:235\u2013254. https:\/\/doi.org\/10.1007\/s40674-018-0102-6","journal-title":"Curr Treatm Opt Rheumatol"},{"key":"6511_CR5","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1007\/s10067-018-4043-0","volume":"37","author":"S Bellando-Randone","year":"2018","unstructured":"Bellando-Randone S, Bruni C, Lepri G et al (2018) The safety of iloprost in systemic sclerosis in a real-life experience. Clin Rheumatol 37:1249\u20131255. https:\/\/doi.org\/10.1007\/s10067-018-4043-0","journal-title":"Clin Rheumatol"},{"key":"6511_CR6","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X221137125","volume":"14","author":"R Bixio","year":"2022","unstructured":"Bixio R, Adami G, Bertoldo E et al (2022) Higher body mass index is associated with a lower iloprost infusion rate tolerance and higher iloprost-related adverse events in patients with systemic sclerosis. Ther Adv Musculoskelet Dis 14:1759720X2211371. https:\/\/doi.org\/10.1177\/1759720X221137125","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"6511_CR7","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s00296-016-3582-4","volume":"37","author":"R Foti","year":"2017","unstructured":"Foti R, Visalli E, Amato G et al (2017) Long-term clinical stabilization of scleroderma patients treated with a chronic and intensive IV iloprost regimen. Rheumatol Int 37:245\u2013249. https:\/\/doi.org\/10.1007\/s00296-016-3582-4","journal-title":"Rheumatol Int"},{"key":"6511_CR8","doi-asserted-by":"publisher","first-page":"10150","DOI":"10.3390\/ijms231710150","volume":"23","author":"T Colasanti","year":"2022","unstructured":"Colasanti T, Stefanantoni K, Fantini C et al (2022) The prostacyclin analogue iloprost modulates CXCL10 in systemic sclerosis. Int J Mol Sci 23:10150. https:\/\/doi.org\/10.3390\/ijms231710150","journal-title":"Int J Mol Sci"},{"key":"6511_CR9","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1002\/art.41536","volume":"73","author":"PS Tsou","year":"2021","unstructured":"Tsou PS, Palisoc PJ, Flavahan NA, Khanna D (2021) Dissecting the cellular mechanism of prostacyclin analog iloprost in reversing vascular dysfunction in scleroderma. Arthritis and Rheumatology 73:520\u2013529. https:\/\/doi.org\/10.1002\/art.41536","journal-title":"Arthritis and Rheumatology"},{"key":"6511_CR10","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s10238-019-00553-y","volume":"19","author":"S Negrini","year":"2019","unstructured":"Negrini S, Magnani O, Matucci-Cerinic M et al (2019) Iloprost use and medical management of systemic sclerosis-related vasculopathy in Italian tertiary referral centers: results from the PROSIT study. Clin Exp Med 19:357\u2013366. https:\/\/doi.org\/10.1007\/s10238-019-00553-y","journal-title":"Clin Exp Med"},{"issue":"4","key":"6511_CR11","first-page":"179","volume":"106","author":"M Colaci","year":"2017","unstructured":"Colaci M, Lumetti F, Giuggioli D, Guiducci S, Bellando-Randone S, Fiori G, Matucci-Cerinic M, Ferri C (2017) Long-term treatment of scleroderma-related digital ulcers with iloprost: a cohort study. Clin Exp Rheumatol 106(4):179\u2013183 Epub 2017 Sep 18","journal-title":"Clin Exp Rheumatol"},{"key":"6511_CR12","doi-asserted-by":"publisher","first-page":"104404","DOI":"10.1016\/j.mvr.2022.104404","volume":"144","author":"E de Lorenzis","year":"2022","unstructured":"de Lorenzis E, Natalello G, Verardi L et al (2022) Sudden winter iloprost withdrawal in scleroderma patients during COVID-19 pandemic. Microvasc Res 144:104404. https:\/\/doi.org\/10.1016\/j.mvr.2022.104404","journal-title":"Microvasc Res"},{"issue":"2","key":"6511_CR13","first-page":"122","volume":"1","author":"P Martins","year":"2022","unstructured":"Martins P, Dourado E, Fonseca JE, Rom\u00e3o V, Resende C (2022) The safety and persistence of intravenous iloprost in systemic sclerosis. ARP Rheumatol 1(2):122\u2013128","journal-title":"ARP Rheumatol"},{"key":"6511_CR14","doi-asserted-by":"publisher","first-page":"158","DOI":"10.4081\/reumatismo.2012.158","volume":"64","author":"S Casigliani Rabl","year":"2012","unstructured":"Casigliani Rabl S, Della Rossa A, Pepe P et al (2012) Long-term cyclic intravenous iloprost in systemic sclerosis: clinical experience from a single center. Reumatismo 64:158\u2013165. https:\/\/doi.org\/10.4081\/reumatismo.2012.158","journal-title":"Reumatismo"},{"key":"6511_CR15","doi-asserted-by":"publisher","first-page":"NP1","DOI":"10.1177\/2397198318765596","volume":"4","author":"MH Fartura Braga Temido","year":"2019","unstructured":"Fartura Braga Temido MH, Gomes M, Parente F, Santos L (2019) Iloprost infusion through elastomeric pump in the treatment of Raynaud\u2019s phenomenon and digital ulcers. J Scleroderma Relat Disord 4:NP1\u2013NP4. https:\/\/doi.org\/10.1177\/2397198318765596","journal-title":"J Scleroderma Relat Disord"},{"key":"6511_CR16","doi-asserted-by":"publisher","unstructured":"Jamart C, Levesque H, Thietart S et al (2022) Iloprost duration for digital ulcers in systemic sclerosis: French retrospective study at two centers and literature review. Front Med (Lausanne) 9:878970. https:\/\/doi.org\/10.3389\/fmed.2022.878970","DOI":"10.3389\/fmed.2022.878970"},{"key":"6511_CR17","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.3899\/jrheum.151437","volume":"43","author":"AA Shah","year":"2016","unstructured":"Shah AA, Schiopu E, Chatterjee S et al (2016) The recurrence of digital ulcers in patients with systemic sclerosis after discontinuation of oral treprostinil. Journal of Rheumatology 43:1665\u20131671. https:\/\/doi.org\/10.3899\/jrheum.151437","journal-title":"Journal of Rheumatology"},{"key":"6511_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/ar4216","volume":"15","author":"AA Shah","year":"2013","unstructured":"Shah AA, Schiopu E, Hummers LK et al (2013) Open label study of escalating doses of oral treprostinil diethanolamine in patients with systemic sclerosis and digital ischemia: pharmacokinetics and correlation with digital perfusion. Arthritis Res Ther 15:R54. https:\/\/doi.org\/10.1186\/ar4216","journal-title":"Arthritis Res Ther"},{"issue":"Suppl 125","key":"6511_CR19","first-page":"181","volume":"38","author":"N del Papa","year":"2020","unstructured":"del Papa N, Vitali C, Bilia S et al (2020) Selexipag may be effective in inducing digital ulcers healing in patients with systemic sclerosis. Clin Exp Rheumatol 38(Suppl 125):181\u2013182","journal-title":"Clin Exp Rheumatol"},{"key":"6511_CR20","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1136\/ard.2010.130658","volume":"70","author":"M Matucci-Cerinic","year":"2011","unstructured":"Matucci-Cerinic M, Denton CP, Furst DE et al (2011) Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 70:32\u201338. https:\/\/doi.org\/10.1136\/ard.2010.130658","journal-title":"Ann Rheum Dis"},{"key":"6511_CR21","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1093\/rheumatology\/keu300","volume":"54","author":"J Meijs","year":"2015","unstructured":"Meijs J, Voskuyl AE, Bloemsaat-Minekus JPJ, Vonk MC (2015) Blood flow in the hands of a predefined homogeneous systemic sclerosis population: the presence of digital ulcers and the improvement with bosentan. Rheumatology (United Kingdom) 54:262\u2013269. https:\/\/doi.org\/10.1093\/rheumatology\/keu300","journal-title":"Rheumatology (United Kingdom)"},{"key":"6511_CR22","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1007\/s10067-013-2172-z","volume":"32","author":"F Cozzi","year":"2013","unstructured":"Cozzi F, Pigatto E, Rizzo M et al (2013) Low occurrence of digital ulcers in scleroderma patients treated with bosentan for pulmonary arterial hypertension: a retrospective case-control study. Clin Rheumatol 32:679\u2013683. https:\/\/doi.org\/10.1007\/s10067-013-2172-z","journal-title":"Clin Rheumatol"},{"key":"6511_CR23","doi-asserted-by":"publisher","unstructured":"Rezus E, Burlui A, Gafton B et al (2019) A patient-centered approach to the burden of symptoms in patients with scleroderma treated with bosentan: a prospective single-center observational study. Exp Ther Med\u00a019(3):1739\u20131746. https:\/\/doi.org\/10.3892\/etm.2019.8361","DOI":"10.3892\/etm.2019.8361"},{"key":"6511_CR24","doi-asserted-by":"publisher","first-page":"229","DOI":"10.5606\/ArchRheumatol.2016.5811","volume":"31","author":"O K\u00fc\u00e7\u00fck\u015fahin","year":"2016","unstructured":"K\u00fc\u00e7\u00fck\u015fahin O, Yildizg\u00f6ren MT, Gerede DM et al (2016) Bosentan for digital ulcers in patients with systemic sclerosis: single center experience. Arch Rheumatol 31:229\u2013233. https:\/\/doi.org\/10.5606\/ArchRheumatol.2016.5811","journal-title":"Arch Rheumatol"},{"key":"6511_CR25","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1111\/j.1365-2133.2011.10581.x","volume":"166","author":"T Taniguchi","year":"2012","unstructured":"Taniguchi T, Asano Y, Hatano M et al (2012) Effects of bosentan on nondigital ulcers in patients with systemic sclerosis. British Journal of Dermatology 166:417\u2013421. https:\/\/doi.org\/10.1111\/j.1365-2133.2011.10581.x","journal-title":"British Journal of Dermatology"},{"key":"6511_CR26","doi-asserted-by":"publisher","unstructured":"Naert A, de Haes P (2013) Successful treatment with bosentan of lower extremity ulcers in a scleroderma patient. Case Rep Med 2013. https:\/\/doi.org\/10.1155\/2013\/690591","DOI":"10.1155\/2013\/690591"},{"key":"6511_CR27","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1177\/0394632015606846","volume":"29","author":"A de Cata","year":"2016","unstructured":"de Cata A, Inglese M, Molinaro F et al (2016) Digital ulcers in scleroderma patients: a retrospective observational study. Int J Immunopathol Pharmacol 29:180\u2013187. https:\/\/doi.org\/10.1177\/0394632015606846","journal-title":"Int J Immunopathol Pharmacol"},{"key":"6511_CR28","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.3899\/jrheum.160592","volume":"43","author":"AC Trombetta","year":"2016","unstructured":"Trombetta AC, Pizzorni C, Ruaro B et al (2016) Effects of longterm treatment with bosentan and iloprost on nailfold absolute capillary number, fingertip blood perfusion, and clinical status in systemic sclerosis. Journal of Rheumatology 43:2033\u20132041. https:\/\/doi.org\/10.3899\/jrheum.160592","journal-title":"Journal of Rheumatology"},{"key":"6511_CR29","doi-asserted-by":"publisher","first-page":"7967","DOI":"10.26355\/eurrev_202211_30149","volume":"26","author":"R Foti","year":"2022","unstructured":"Foti R, Amato G, Benenati A et al (2022) Intravenous iloprost in systemic sclerosis and its effect in cardiopulmonary function: a retrospective observational study. Eur Rev Med Pharmacol Sci 26:7967\u20137973 https:\/\/doi.org\/10.26355\/eurrev_202211_30149","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"6511_CR30","doi-asserted-by":"publisher","first-page":"881","DOI":"10.3899\/jrheum.131284","volume":"41","author":"M Cutolo","year":"2014","unstructured":"Cutolo M, Ruaro B, Pizzorni C et al (2014) Longterm treatment with endothelin receptor antagonist bosentan and iloprost improves fingertip blood perfusion in systemic sclerosis. Journal of Rheumatology 41:881\u2013886. https:\/\/doi.org\/10.3899\/jrheum.131284","journal-title":"Journal of Rheumatology"},{"issue":"2","key":"6511_CR31","first-page":"126","volume":"17","author":"I Sharabi","year":"2015","unstructured":"Sharabi I, Tanay A, Zandman-Goddard G (2015) Digital ulcers, systemic sclerosis sine scleroderma and paraneoplastic phenomena responding to bosentan therapy. Isr Med Assoc J. 17(2):126\u2013127","journal-title":"Isr Med Assoc J."},{"key":"6511_CR32","doi-asserted-by":"publisher","first-page":"824","DOI":"10.3390\/jcm9030824","volume":"9","author":"FC Enevoldsen","year":"2020","unstructured":"Enevoldsen FC, Sahana J, Wehland M et al (2020) Endothelin receptor antagonists: status quo and future perspectives for targeted therapy. J Clin Med 9:824. https:\/\/doi.org\/10.3390\/jcm9030824","journal-title":"J Clin Med"},{"key":"6511_CR33","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1001\/jama.2016.5258","volume":"315","author":"D Khanna","year":"2016","unstructured":"Khanna D, Denton CP, Merkel PA et al (2016) Effect of macitentan on the development of new ischemic digital ulcers in patients with systemic sclerosis: Dual-1 and Dual-2 randomized clinical trials. JAMA 315:1975\u20131988. https:\/\/doi.org\/10.1001\/jama.2016.5258","journal-title":"JAMA"},{"key":"6511_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2016\/1718309","volume":"2016","author":"E Giner Serret","year":"2016","unstructured":"Giner Serret E (2016) Swift and complete healing of digital ulcers after macitentan treatment. Case Rep Rheumatol 2016:1\u20134. https:\/\/doi.org\/10.1155\/2016\/1718309","journal-title":"Case Rep Rheumatol"},{"key":"6511_CR35","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2018-228295","volume":"12","author":"T Gon\u00e7alves","year":"2019","unstructured":"Gon\u00e7alves T, Santos L (2019) Macitentan in the treatment of severe digital ulcers. BMJ Case Rep 12:e228295. https:\/\/doi.org\/10.1136\/bcr-2018-228295","journal-title":"BMJ Case Rep"},{"key":"6511_CR36","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1093\/rheumatology\/ket019","volume":"52","author":"S Parisi","year":"2013","unstructured":"Parisi S, Peroni CL, Lagan\u00e0 A et al (2013) Efficacy of ambrisentan in the treatment of digital ulcers in patients with systemic sclerosis: a preliminary study. Rheumatology 52:1142\u20131144","journal-title":"Rheumatology"},{"key":"6511_CR37","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.jaad.2014.04.028","volume":"71","author":"L Chung","year":"2014","unstructured":"Chung L, Ball K, Yaqub A et al (2014) Effect of the endothelin type A-selective endothelin receptor antagonist ambrisentan on digital ulcers in patients with systemic sclerosis: results of a prospective pilot study. J Am Acad Dermatol 71:400\u2013401. https:\/\/doi.org\/10.1016\/j.jaad.2014.04.028","journal-title":"J Am Acad Dermatol"},{"key":"6511_CR38","doi-asserted-by":"publisher","unstructured":"Bose N, Bena J, Chatterjee S (2015) Evaluation of the effect of ambrisentan on digital microvascular flow in patients with systemic sclerosis using laser Doppler perfusion imaging: a 12-week randomized double-blind placebo controlled trial. Arthritis Res Ther\u00a017(1):44. https:\/\/doi.org\/10.1186\/s13075-015-0558-9","DOI":"10.1186\/s13075-015-0558-9"},{"key":"6511_CR39","doi-asserted-by":"publisher","unstructured":"Hou Z, Su X, Han G et al (2022) JAK1\/2 Inhibitor baricitinib improves skin fibrosis and digital ulcers in systemic sclerosis. Front Med (Lausanne)\u00a09:859330. https:\/\/doi.org\/10.3389\/fmed.2022.859330","DOI":"10.3389\/fmed.2022.859330"},{"key":"6511_CR40","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14876","volume":"32","author":"SC Deverapalli","year":"2018","unstructured":"Deverapalli SC, Rosmarin D (2018) The use of JAK inhibitors in the treatment of progressive systemic sclerosis. Journal of the European Academy of Dermatology and Venereology 32:e328","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"key":"6511_CR41","doi-asserted-by":"publisher","first-page":"25","DOI":"10.4252\/wjsc.v3.i4.25","volume":"3","author":"L Casteilla","year":"2011","unstructured":"Casteilla L (2011) Adipose-derived stromal cells: their identity and uses in clinical trials, an update. World J Stem Cells 3:25. https:\/\/doi.org\/10.4252\/wjsc.v3.i4.25","journal-title":"World J Stem Cells"},{"key":"6511_CR42","doi-asserted-by":"publisher","unstructured":"Papa N del, di Luca G, Sambataro D, et al (2015) Regional implantation of autologous adipose tissue-derived cells induces a prompt healing of long-lasting indolent digital ulcers in patients with systemic sclerosis. Cell Transplant 24:2297\u20132305. https:\/\/doi.org\/10.3727\/096368914X685636","DOI":"10.3727\/096368914X685636"},{"key":"6511_CR43","doi-asserted-by":"publisher","unstructured":"Bene M del, Pozzi MR, Rovati L, et al (2014) Autologous fat grafting for scleroderma-induced digital ulcers an effective technique in patients with systemic sclerosis. Handchirurgie Mikrochirurgie Plastische Chirurgie 46:242\u2013247. https:\/\/doi.org\/10.1055\/s-0034-1376970","DOI":"10.1055\/s-0034-1376970"},{"key":"6511_CR44","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13075-018-1792-8","volume":"21","author":"N del Papa","year":"2019","unstructured":"del Papa N, di Luca G, Andracco R et al (2019) Regional grafting of autologous adipose tissue is effective in inducing prompt healing of indolent digital ulcers in patients with systemic sclerosis: results of a monocentric randomized controlled study. Arthritis Res Ther 21:7. https:\/\/doi.org\/10.1186\/s13075-018-1792-8","journal-title":"Arthritis Res Ther"},{"key":"6511_CR45","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1093\/rheumatology\/ket432","volume":"53","author":"G Takagi","year":"2014","unstructured":"Takagi G, Miyamoto M, Tara S et al (2014) Therapeutic vascular angiogenesis for intractable macroangiopathy-related digital ulcer in patients with systemic sclerosis: a pilot study. Rheumatology (United Kingdom) 53:854\u2013859. https:\/\/doi.org\/10.1093\/rheumatology\/ket432","journal-title":"Rheumatology (United Kingdom)"},{"key":"6511_CR46","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.3904\/kjim.2018.199","volume":"34","author":"JW Souk","year":"2019","unstructured":"Souk JW, Kim HS (2019) Effects of botulinum toxin injection on systemic sclerosis-related digital ulcers. Korean Journal of Internal Medicine 34:1169\u20131170","journal-title":"Korean Journal of Internal Medicine"},{"key":"6511_CR47","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/1346-8138.13030","volume":"43","author":"SI Motegi","year":"2016","unstructured":"Motegi SI, Yamada K, Toki S et al (2016) Beneficial effect of botulinum toxin A on Raynaud\u2019s phenomenon in Japanese patients with systemic sclerosis: a prospective, case series study. Journal of Dermatology 43:56\u201362. https:\/\/doi.org\/10.1111\/1346-8138.13030","journal-title":"Journal of Dermatology"},{"key":"6511_CR48","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1111\/1346-8138.14140","volume":"45","author":"SI Motegi","year":"2018","unstructured":"Motegi SI, Sekiguchi A, Saito S et al (2018) Successful treatment of Raynaud\u2019s phenomenon and digital ulcers in systemic sclerosis patients with botulinum toxin B injection: assessment of peripheral vascular disorder by angiography and dermoscopic image of nail fold capillary. Journal of Dermatology 45:349\u2013352. https:\/\/doi.org\/10.1111\/1346-8138.14140","journal-title":"Journal of Dermatology"},{"key":"6511_CR49","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1007\/s00296-020-04606-4","volume":"41","author":"M Nagarajan","year":"2021","unstructured":"Nagarajan M, McArthur P (2021) Targeted high concentration botulinum toxin A injections in patients with Raynaud\u2019s phenomenon: a retrospective single-centre experience. Rheumatol Int 41:943\u2013949. https:\/\/doi.org\/10.1007\/s00296-020-04606-4","journal-title":"Rheumatol Int"},{"key":"6511_CR50","doi-asserted-by":"publisher","first-page":"843","DOI":"10.2340\/00015555-2665","volume":"97","author":"SI Motegi","year":"2017","unstructured":"Motegi SI, Uehara A, Yamada K et al (2017) Efficacy of botulinum toxin B injection for Raynaud\u2019s phenomenon and digital ulcers in patients with systemic sclerosis. Acta Derm Venereol 97:843\u2013850. https:\/\/doi.org\/10.2340\/00015555-2665","journal-title":"Acta Derm Venereol"},{"key":"6511_CR51","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s10067-021-05900-7","volume":"41","author":"S Shenavandeh","year":"2022","unstructured":"Shenavandeh S, Sepaskhah M, Dehghani S, Nazarinia MA (2022) A 4-week comparison of capillaroscopy changes, healing effect, and cost-effectiveness of botulinum toxin-A vs prostaglandin analog infusion in refractory digital ulcers in systemic sclerosis. Clin Rheumatol 41:95\u2013104. https:\/\/doi.org\/10.1007\/s10067-021-05900-7","journal-title":"Clin Rheumatol"},{"key":"6511_CR52","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1002\/micr.22379","volume":"35","author":"A Momeni","year":"2015","unstructured":"Momeni A, Sorice SC, Valenzuela A et al (2015) Surgical treatment of systemic sclerosis - is it justified to offer peripheral sympathectomy earlier in the disease process? Microsurgery 35:441\u2013446. https:\/\/doi.org\/10.1002\/micr.22379","journal-title":"Microsurgery"},{"key":"6511_CR53","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1186\/s13075-019-1979-7","volume":"21","author":"V Nagaraja","year":"2019","unstructured":"Nagaraja V, Spino C, Bush E et al (2019) A multicenter randomized, double-blind, placebo-controlled pilot study to assess the efficacy and safety of riociguat in systemic sclerosis-associated digital ulcers. Arthritis Res Ther 21:202. https:\/\/doi.org\/10.1186\/s13075-019-1979-7","journal-title":"Arthritis Res Ther"},{"key":"6511_CR54","first-page":"210","volume":"43","author":"M Hassanien","year":"2018","unstructured":"Hassanien M, Rashad S, Mohamed N et al (2018) Non-invasive oxygen-ozone therapy in treating digital ulcers of patients with systemic sclerosis. Acta Reumatol Port 43:210\u2013216","journal-title":"Acta Reumatol Port"},{"key":"6511_CR55","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1093\/mr\/roab117","volume":"32","author":"S Kaymaz","year":"2022","unstructured":"Kaymaz S, Karasu U, Alkan H et al (2022) Efficacy of local oxygen\u2013ozone therapy for the treatment of digital ulcer refractory to medical therapy in systemic sclerosis: a randomized controlled study. Mod Rheumatol 32:1102\u20131107. https:\/\/doi.org\/10.1093\/mr\/roab117","journal-title":"Mod Rheumatol"},{"key":"6511_CR56","first-page":"864","volume":"57","author":"MA Ortega","year":"2021","unstructured":"Ortega MA, Fraile-Martinez O, Garc\u00eda-Montero C et al (2021) A general overview on the hyperbaric oxygen therapy: applications, mechanisms and translational opportunities. Medicina (Lithuania) 57:864","journal-title":"Medicina (Lithuania)"},{"key":"6511_CR57","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1111\/ijd.13570","volume":"56","author":"B Mirasoglu","year":"2017","unstructured":"Mirasoglu B, Bagli BS, Aktas S (2017) Hyperbaric oxygen therapy for chronic ulcers in systemic sclerosis \u2013 case series. Int J Dermatol 56:636\u2013640. https:\/\/doi.org\/10.1111\/ijd.13570","journal-title":"Int J Dermatol"},{"key":"6511_CR58","first-page":"20","volume":"40","author":"C Gerodimos","year":"2013","unstructured":"Gerodimos C, Stefanidou S, Kotsiou M, Melekos T, Mesimeris T (2013) Hyperbaric oxygen treatment of intractable ulcers in a systemic sclerosis patient. Aristotle University Medical Journal. Aristotle University Medical Journal 40:20\u201322","journal-title":"Aristotle University Medical Journal"},{"key":"6511_CR59","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1620\/tjem.238.39","volume":"238","author":"S Saito","year":"2015","unstructured":"Saito S, Ishii T, Kamogawa Y et al (2015) Extracorporeal shock wave therapy for digital ulcers of systemic sclerosis: a phase 2 pilot study. Tohoku Journal of Experimental Medicine 238:39\u201347. https:\/\/doi.org\/10.1620\/tjem.238.39","journal-title":"Tohoku Journal of Experimental Medicine"},{"key":"6511_CR60","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1080\/09546634.2018.1484875","volume":"30","author":"M Hughes","year":"2019","unstructured":"Hughes M, Moore T, Manning J et al (2019) A feasibility study of a novel low-level light therapy for digital ulcers in systemic sclerosis. Journal of Dermatological Treatment 30:251\u2013257. https:\/\/doi.org\/10.1080\/09546634.2018.1484875","journal-title":"Journal of Dermatological Treatment"},{"key":"6511_CR61","doi-asserted-by":"publisher","first-page":"208","DOI":"10.3389\/fmed.2019.00208","volume":"6","author":"P Korsten","year":"2019","unstructured":"Korsten P, M\u00fcller GA, Rademacher JG et al (2019) Rheopheresis for digital ulcers and Raynaud\u2019s phenomenon in systemic sclerosis refractory to conventional treatments. Front Med (Lausanne) 6:208. https:\/\/doi.org\/10.3389\/fmed.2019.00208","journal-title":"Front Med (Lausanne)"},{"key":"6511_CR62","doi-asserted-by":"publisher","unstructured":"Rademacher JG, Tampe B, Borisch A et al (2022) Study protocol: a randomized controlled prospective single-center feasibility study of Rheopheresis for Raynaud\u2019s syndrome and digital ulcers in systemic sclerosis (RHEACT Study). Front Med\u00a09:871744. https:\/\/doi.org\/10.3389\/fmed.2022.871744","DOI":"10.3389\/fmed.2022.871744"},{"key":"6511_CR63","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2022.105348","volume":"89","author":"S Keret","year":"2022","unstructured":"Keret S, Slobodin G, Awisat A et al (2022) G- CSF treatment for refractory digital ulcers in systemic sclerosis. Joint Bone Spine 89:105348. https:\/\/doi.org\/10.1016\/j.jbspin.2022.105348","journal-title":"Joint Bone Spine"},{"key":"6511_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.lpm.2021.104064","volume":"50","author":"M Hughes","year":"2021","unstructured":"Hughes M, Bruni C, Ruaro B et al (2021) Digital ulcers in systemic sclerosis. Presse Med 50:104064. https:\/\/doi.org\/10.1016\/j.lpm.2021.104064","journal-title":"Presse Med"},{"key":"6511_CR65","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","volume":"76","author":"O Kowal-Bielecka","year":"2017","unstructured":"Kowal-Bielecka O, Fransen J, Avouac J et al (2017) Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis 76:1327\u20131339. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209909","journal-title":"Ann Rheum Dis"},{"key":"6511_CR66","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1136\/annrheumdis-2014-207001","volume":"75","author":"E Hachulla","year":"2016","unstructured":"Hachulla E, Hatron PY, Carpentier P et al (2016) Efficacy of sildenafil on ischaemic digital ulcer healing in systemic sclerosis: the placebo-controlled SEDUCE study. Ann Rheum Dis 75:1009\u20131015. https:\/\/doi.org\/10.1136\/annrheumdis-2014-207001","journal-title":"Ann Rheum Dis"},{"key":"6511_CR67","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1007\/s10067-020-04966-z","volume":"39","author":"A Fern\u00e1ndez-Codina","year":"2020","unstructured":"Fern\u00e1ndez-Codina A, Kazem M, Pope JE (2020) Possible benefit of tadalafil cream for the treatment of Raynaud\u2019s phenomenon and digital ulcers in systemic sclerosis. Clin Rheumatol 39:963\u2013965","journal-title":"Clin Rheumatol"},{"key":"6511_CR68","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1007\/s00508-020-01669-y","volume":"133","author":"D Perkovi\u0107","year":"2021","unstructured":"Perkovi\u0107 D, Petri\u0107 M, Bo\u017ei\u0107 I et al (2021) Low dose intravenous immunoglobulin in addition to cyclophosphamide in systemic sclerosis: single centre experience. Wien Klin Wochenschr 133:1070\u20131075. https:\/\/doi.org\/10.1007\/s00508-020-01669-y","journal-title":"Wien Klin Wochenschr"},{"key":"6511_CR69","doi-asserted-by":"publisher","first-page":"250","DOI":"10.2340\/00015555-1678","volume":"94","author":"T Inoue","year":"2014","unstructured":"Inoue T, Yamaoka T, Murota H et al (2014) Effective oral psoralen plus ultraviolet a therapy for digital ulcers with revascularization in systemic sclerosis. Acta Derm Venereol 94:250\u2013251","journal-title":"Acta Derm Venereol"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-023-06511-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-023-06511-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-023-06511-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,13]],"date-time":"2023-11-13T14:05:56Z","timestamp":1699884356000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-023-06511-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,27]]},"references-count":69,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["6511"],"URL":"https:\/\/doi.org\/10.1007\/s10067-023-06511-0","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,27]]},"assertion":[{"value":"9 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"DD has received speaking fees and an honorarium for participation in an advisory board from ELPEN. All other authors have disclosed no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}